Non-Proteinuric Diabetic Nephropathy

Nicolas Roberto Robles, Juan Villa, Roman Hernandez Gallego, Nicolas Roberto Robles, Juan Villa, Roman Hernandez Gallego

Abstract

Diabetic nephropathy patients traditionally show significant macroalbuminuria prior to the development of renal impairment. However, this clinical paradigm has recently been questioned. Epidemiological surveys confirm that chronic kidney disease (CKD) diagnosed by a low glomerular filtration rate (GFR) is more common in diabetic patients than in the non-diabetic population but a low number of patients had levels of proteinuria above that which traditionally defines overt diabetic nephropathy (>500 mg/g). The large number of patients with low levels of proteinuria suggests that the traditional clinical paradigm of overt diabetic nephropathy is changing since it does not seem to be the underlying renal lesion in most of diabetic subjects with CKD.

Keywords: chronic kidney disease; diabetes mellitus; microalbuminuria; proteinuria.

References

    1. Whiting D., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 2011;94:311–321. doi: 10.1016/j.diabres.2011.10.029.
    1. De Boer I.H., Rue T.C., Hall Y.N., Heagerty P.J., Weiss N.S., Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–2539. doi: 10.1001/jama.2011.861.
    1. Parving H., Lewis J., Ravid M., Remuzzi G., Hunsicker L.G. (DEMAND investigators). Prevalence and risk factors for microalbuminuria in a referred cohort of Type 2 diabetic patients: A global perspective. Kidney Int. 2006;69:2057–2063. doi: 10.1038/sj.ki.5000377.
    1. US Renal Data System . USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2012.
    1. Hill C.J., Fogarty D.G. Changing trends in end-stage renal disease due to diabetes in the United Kingdom. J. Ren. Care. 2012;38(Suppl. 1):12–22. doi: 10.1111/j.1755-6686.2012.00273.x.
    1. Grace B., Clayton P., McDonald S. Increases in renal replacement therapy in Australia and New Zealand: Understanding trends in diabetic nephropathy. Nephrology (Carlton) 2012;17:76–84. doi: 10.1111/j.1440-1797.2011.01512.x.
    1. Collins A.J., Kasiske B., Herzog C., Chavers B., Foley R., Gilbertson D., Grimm R., Liu J., Louis T., Manning W., et al. United States Renal Data System: Excerpts from the United States Renal Data System 2004 annual data report: Atlas of end-stage renal disease in the United States. Am. J. Kidney Dis. 2005;45:A5–A7. doi: 10.1053/j.ajkd.2004.10.009.
    1. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. (UKPDS GROUP). Development and progression of nephropathy in Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int. 2003;63:225–232. doi: 10.1046/j.1523-1755.2003.00712.x.
    1. Ismail N., Becker B., Strzelczyk P., Ritz E. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int. 1999;55:1–28. doi: 10.1046/j.1523-1755.1999.00232.x.
    1. Parving H.H., Mauer M., Ritz E. Diabetic nephropathy. In: Brenner B., editor. Brenner and Rector’s The Kidney. 8th ed. Volume 2. Saunders; Philadelphia, PA, USA: 2007. pp. 1265–1298.
    1. Stokes M.B., Markowitz G.S., D’Agati V.D. The modern spectrum of renal biopsy findings in patients with diabetes. Clin. J. Am. Soc. Nephrol. 2013;8:1718–1724.
    1. Groop P.H., Thomas M.C., Moran J.L., Wadèn J., Thorn L.M., Mäkinen V.P., Rosengård-Bärlund M., Saraheimo M., Hietala K., Heikkilä O., et al. The presence and severity of chronic kidney disease predicts all-cause mortality in Type 1 diabetes. Diabetes. 2009;58:1651–1658. doi: 10.2337/db08-1543.
    1. Orchard T.J., Dorman J.S., Maser R.E., Becker D.J., Drash A.L., Ellis D., LaPorte R.E., Kuller L.H. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39:1116–1124. doi: 10.2337/diab.39.9.1116.
    1. Hovind P., Rossing P., Tarnow L., Smidt U.M., Parving H.H. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–709. doi: 10.1046/j.1523-1755.2001.059002702.x.
    1. Robles N., Fernández-Carbonero E., Sánchez Casado E., Cuberto J. Growing incidence of diabetic nephropathy in the region of Badajoz during the period 1991–2006. Nefrologia. 2009;29:244–248.
    1. Hostetter T.H. Diabetic Nephropathy. In: Brenner B.M., Rector F.C., editors. The Kidney. 4th ed. Volume II. Saunders; Londres, UK: 1991. pp. 1695–1727.
    1. Tervaert T.W., Mooyaart A.L., Amann K., Cohen A.H., Cook H.T., Drachenberg C.B., Ferrario F., Fogo A.B., Haas M., de Heer E., et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 2010;21:556–563. doi: 10.1681/ASN.2010010010.
    1. Rasch R., Nörgaard J.O. Renal enlargement: Comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia. 1983;25:280–287. doi: 10.1007/BF00279944.
    1. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., Nelson R.G., Myers B.D., Rennke H.G., Coplon N.S., Sun L., Meyer T.W. Podocyte loss and progressive glomerular injury in Type 2 diabetes. J. Clin. Investig. 1997;99:342–348. doi: 10.1172/JCI119163.
    1. MacIsaac R.J., Tsalamandris C., Panagiotopoulos S., Smith T.J., McNeil K.J., Jerums G. Nonalbuminuric renal insufficiency in Type 2 diabetes. Diabetes Care. 2004;27:195–200. doi: 10.2337/diacare.27.1.195.
    1. Garg A.X., Kiberd B.A., Clark W.F., Haynes R.B., Clase C.M. Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney Int. 2002;61:2165–2175. doi: 10.1046/j.1523-1755.2002.00356.x.
    1. Kramer H.J., Nguyen Q.D., Curhan G., Hsu C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with Type 2 diabetes mellitus. JAMA. 2003;289:3273–3277. doi: 10.1001/jama.289.24.3273.
    1. Penno G., Solini A., Bonora E., Fondelli C., Orsi E., Zerbini G., Trevisan R., Vedovato M., Gruden G., Cavalot F., et al. Clinical significance of nonalbuminuric renal impairment in Type 2 diabetes. J. Hypertens. 2011;29:1802–1809. doi: 10.1097/HJH.0b013e3283495cd6.
    1. Thomas M.C., Macisaac R.J., Jerums G., Weekes A., Moran J., Shaw J.E., Atkins R.C. Nonalbuminuric renal impairment in Type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11) Diabetes Care. 2009;32:1497–1502. doi: 10.2337/dc08-2186.
    1. Retnakaran R., Cull C.A., Thorne K.I., Adler A.I., Holman R.R. (UKPDS Study Group). Risk factors for renal dysfunction in Type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55:1832–1839. doi: 10.2337/db05-1620.
    1. Ninomiya T., Perkovic V., de Galan B.E., Zoungas S., Pillai A., Jardine M., Patel A., Cass A., Neal B., Poulter N., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 2009;20:1813–1821. doi: 10.1681/ASN.2008121270.
    1. Rigalleau V., Lasseur C., Raffaitin C., Beauvieux M.C., Barthe N., Chauveau P., Combe C., Gin H. Normoalbuminuric renal insufficient diabetic patients: A lower risk group. Diabetes Care. 2007;30:2034–2039. doi: 10.2337/dc07-0140.
    1. Moriya T., Moriya R., Yajima Y., Steffes M.W., Mauer M. Urinary albumin as an indicator of diabetic nephropathy lesions in Japanese Type 2 diabetic patients. Nephron. 2002;91:292–299. doi: 10.1159/000058407.
    1. Fioretto P., Stehouwer C.D., Mauer M., Chiesura-Corona M., Brocco E., Carraro A., Bortoloso E., van Hinsbergh V.W., Crepaldi G., Nosadini R. Heterogeneous nature of microalbuminuria in NIDDM: Studies of endothelial function and renal structure. Diabetologia. 1998;41:233–236. doi: 10.1007/s001250050895.
    1. Fioretto P., Mauer M., Brocco E., Velussi M., Frigato F., Muollo B., Sambataro M., Abaterusso C., Baggio B., Crepaldi G., et al. Patterns of renal injury in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1996;39:1569–1576. doi: 10.1007/s001250050616.
    1. Brocco E., Fioretto P., Mauer M., Saller A., Carraro A., Frigato F., Chiesura-Corona M., Bianchi L., Baggio B., Maioli M., et al. Renal structure and function in non-insulin-dependent diabetic patients with microalbuminuria. Kidney Int. 1997;52:S40–S44.
    1. Fioretto P., Mauer M. Histopathology of diabetic nephropathy. Semin. Nephrol. 2007;27:195–207. doi: 10.1016/j.semnephrol.2007.01.012.
    1. Dalla Vestra M., Saller A., Bortoloso E., Mauer M., Fioretto P. Structural involvement in Type 1 and Type 2 diabetic nephropathy. Diabetes Metab. 2000;26(Suppl. 4):8–14.
    1. Caramori M.L., Fioretto P., Mauer M. Low glomerular filtration rate in normoalbuminuric Type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036–1040. doi: 10.2337/diabetes.52.4.1036.
    1. Tsalamandris C., Allen T.J., Gilbert R.E., Sinha A., Panagiotopoulos S., Cooper M.E., Jerums G. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43:649–655. doi: 10.2337/diab.43.5.649.
    1. Perkins B., Ficociello L., Roshan B., Warram J.H., Krolewski A.S. In patients with Type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2001;77:57–64. doi: 10.1038/ki.2009.399.
    1. Bash L.D., Selvin E., Steffes M., Coresh J., Astor B.C. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch. Intern. Med. 2008;168:2440–2447. doi: 10.1001/archinte.168.22.2440.
    1. Jerums G., Premaratne E., Panagiotopoulos S., Clarke S., Power D.A., MacIsaac R.J. New and old markers of progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 2008;82(Suppl. 1):S30–S37. doi: 10.1016/j.diabres.2008.09.032.
    1. Messerli F.H., Panjrath G.S. The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension Exactly How Essential? J. Am. Coll. Cardiol. 2009;54:1827–1834. doi: 10.1016/j.jacc.2009.05.073.
    1. Wald R., Quinn R.R., Luo J., Li P., Scales D.C., Mamdani M.M., Ray J.G. (University of Toronto Acute Kidney Injury Research Group). Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302:1179–1185. doi: 10.1001/jama.2009.1322.
    1. Ishani A., Xue J., Himmelfarb J., Eggers P.W., Kimmel P.L., Molitoris B.A., Collins A.J. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 2009;20:223–228. doi: 10.1681/ASN.2007080837.
    1. Hsu C.Y., McCulloch C.E., Fan D., Ordoñez J.D., Chertow G.M., Go A.S. Community-based incidence of acute renal failure. Kidney Int. 2007;72:208–212. doi: 10.1038/sj.ki.5002297.
    1. Centers for Disease Control and Prevention (CDC) Prevalence of chronic kidney disease and associated risk factors–United States, 1999–2004. MMWR Morb. Mortal. Wkly. Rep. 2007;56:161–165.
    1. Onuigbo M.A.C. Can ACE Inhibitors and Angiotensin Receptor Blockers Be Detrimental in CKD Patients? Nephron Clin. Pract. 2011;118:c407–c419. doi: 10.1159/000324164.
    1. Rahman M., Pressel S., Davis B.R., Nwachuku C., Wright J.T., Jr., Whelton P.K., Barzilay J., Batuman V., Eckfeldt J.H., Farber M., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch. Intern. Med. 2005;165:936–946.
    1. Ponte B., Felipe C., Muriel A., Tenorio M.T., Liano F. Long-term functional evolution after an acute kidney injury: A 10-year study. Nephrol. Dial. Transplant. 2008;23:3859–3866. doi: 10.1093/ndt/gfn398.
    1. Onuigbo M.A., Achebe N.J. Acute Kidney Injury on Chronic Kidney Disease-The Rainbow Syndrome of Too Many Colors: A Mayo Clinic Health System Case Series Report. In: Onuigbo M.A.C., editor. ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics. Volume 1. NOVA Publishers; New York, NY, USA: 2013. pp. 91–108.
    1. Onuigbo M.A. Syndrome of rapid-onset end-stage renal disease: A new unrecognized pattern of CKD progression to ESRD. Ren. Fail. 2010;32:954–958. doi: 10.3109/0886022X.2010.502608.
    1. Onuigbo M.A., Agbasi N. Diabetic Nephropathy and CKD-Analysis of Individual Patient Serum Creatinine Trajectories: A Forgotten Diagnostic Methodology for Diabetic CKD Prognostication and Prediction. J. Clin. Med. 2015;4:1348–1368. doi: 10.3390/jcm4071348.
    1. Packham D.K., Ivory S.E., Reutens A.T., Wolfe R., Rohde R., Lambers Heerspink H., Dwyer J.P., Atkins R.C., Lewis J. (Collaborative Study Group). Proteinuria in Type 2 diabetic patients with renal impairment: The changing face of diabetic nephropathy. Nephron Clin. Pract. 2011;118:c331–c338. doi: 10.1159/000323139.
    1. Onuigbo M.A., Onuigbo N.T. Use of ultrahigh RAAS blockade: Implications for exacerbation of renal failure. Kidney Int. 2006;69:194–195. doi: 10.1038/sj.ki.5000068.
    1. Suissa S., Hutchinson T., Brophy J.M., Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69:913–919. doi: 10.1038/sj.ki.5000159.
    1. Ahmed A.K., Kamath N.S., El Kossi M., El Nahas A.M. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol. Dial. Transplant. 2010;25:3977–3982. doi: 10.1093/ndt/gfp511.
    1. Rychlik I., Fliser D., Ritz E. Non-diabetic renal disease in Type 2 diabetes mellitus. In: Ritz E., Rychlik I., editors. Nephropathy in Type 2 Diabetes. Oxford University Press; Oxford, UK: 1999. pp. 7–88.
    1. Yasuno S., Ueshima K., Oba K., Fujimoto A., Ogihara T., Saruta T., Nakao K. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J. Hypertens. 2009;27:1705–1712. doi: 10.1097/HJH.0b013e32832c6968.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever